The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Influenza NA Inhibitor Market Research Report 2025
Synopsis
Neuraminidase enzymes are glycoside hydrolase enzymes that cleave (cut) the glycosidic linkages of neuraminic acids. The viral neuraminidases are frequently used as antigenic determinants found on the surface of the influenza virus.
The global Influenza NA Inhibitor market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Influenza NA Inhibitor is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Influenza NA Inhibitor is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Influenza NA Inhibitor include Green Cross, Roche, GlaxoSmithKline, Henan DaKen Chemical, ATK Chemical, Chemwill Asia Co.,Ltd., Shionogi Co., NeoPharm and Moksha8 Pharma, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Influenza NA Inhibitor, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Influenza NA Inhibitor.
Report Scope
The Influenza NA Inhibitor market size, estimations, and forecasts are provided in terms of sales volume (Tons) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Influenza NA Inhibitor market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Influenza NA Inhibitor manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Green Cross
Roche
GlaxoSmithKline
Henan DaKen Chemical
ATK Chemical
Chemwill Asia Co.,Ltd.
Shionogi Co.
NeoPharm
Moksha8 Pharma
Segment by Type
Zanamivir
Oseltamivir
Peramivir
Segment by Application
Influenza A Treatment
Influenza B Treatment
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Influenza NA Inhibitor manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Influenza NA Inhibitor in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Neuraminidase enzymes are glycoside hydrolase enzymes that cleave (cut) the glycosidic linkages of neuraminic acids. The viral neuraminidases are frequently used as antigenic determinants found on the surface of the influenza virus.
The global Influenza NA Inhibitor market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Influenza NA Inhibitor is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Influenza NA Inhibitor is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Influenza NA Inhibitor include Green Cross, Roche, GlaxoSmithKline, Henan DaKen Chemical, ATK Chemical, Chemwill Asia Co.,Ltd., Shionogi Co., NeoPharm and Moksha8 Pharma, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Influenza NA Inhibitor, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Influenza NA Inhibitor.
Report Scope
The Influenza NA Inhibitor market size, estimations, and forecasts are provided in terms of sales volume (Tons) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Influenza NA Inhibitor market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Influenza NA Inhibitor manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Green Cross
Roche
GlaxoSmithKline
Henan DaKen Chemical
ATK Chemical
Chemwill Asia Co.,Ltd.
Shionogi Co.
NeoPharm
Moksha8 Pharma
Segment by Type
Zanamivir
Oseltamivir
Peramivir
Segment by Application
Influenza A Treatment
Influenza B Treatment
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Influenza NA Inhibitor manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Influenza NA Inhibitor in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Influenza NA Inhibitor Market Overview
1.1 Product Overview and Scope of Influenza NA Inhibitor
1.2 Influenza NA Inhibitor Segment by Type
1.2.1 Global Influenza NA Inhibitor Market Value Comparison by Type (2024-2030)
1.2.2 Zanamivir
1.2.3 Oseltamivir
1.2.4 Peramivir
1.3 Influenza NA Inhibitor Segment by Application
1.3.1 Global Influenza NA Inhibitor Market Value by Application: (2024-2030)
1.3.2 Influenza A Treatment
1.3.3 Influenza B Treatment
1.4 Global Influenza NA Inhibitor Market Size Estimates and Forecasts
1.4.1 Global Influenza NA Inhibitor Revenue 2019-2030
1.4.2 Global Influenza NA Inhibitor Sales 2019-2030
1.4.3 Global Influenza NA Inhibitor Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Influenza NA Inhibitor Market Competition by Manufacturers
2.1 Global Influenza NA Inhibitor Sales Market Share by Manufacturers (2019-2024)
2.2 Global Influenza NA Inhibitor Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Influenza NA Inhibitor Average Price by Manufacturers (2019-2024)
2.4 Global Influenza NA Inhibitor Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Influenza NA Inhibitor, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Influenza NA Inhibitor, Product Type & Application
2.7 Influenza NA Inhibitor Market Competitive Situation and Trends
2.7.1 Influenza NA Inhibitor Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Influenza NA Inhibitor Players Market Share by Revenue
2.7.3 Global Influenza NA Inhibitor Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Influenza NA Inhibitor Retrospective Market Scenario by Region
3.1 Global Influenza NA Inhibitor Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Influenza NA Inhibitor Global Influenza NA Inhibitor Sales by Region: 2019-2030
3.2.1 Global Influenza NA Inhibitor Sales by Region: 2019-2024
3.2.2 Global Influenza NA Inhibitor Sales by Region: 2025-2030
3.3 Global Influenza NA Inhibitor Global Influenza NA Inhibitor Revenue by Region: 2019-2030
3.3.1 Global Influenza NA Inhibitor Revenue by Region: 2019-2024
3.3.2 Global Influenza NA Inhibitor Revenue by Region: 2025-2030
3.4 North America Influenza NA Inhibitor Market Facts & Figures by Country
3.4.1 North America Influenza NA Inhibitor Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Influenza NA Inhibitor Sales by Country (2019-2030)
3.4.3 North America Influenza NA Inhibitor Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Influenza NA Inhibitor Market Facts & Figures by Country
3.5.1 Europe Influenza NA Inhibitor Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Influenza NA Inhibitor Sales by Country (2019-2030)
3.5.3 Europe Influenza NA Inhibitor Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Influenza NA Inhibitor Market Facts & Figures by Country
3.6.1 Asia Pacific Influenza NA Inhibitor Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Influenza NA Inhibitor Sales by Country (2019-2030)
3.6.3 Asia Pacific Influenza NA Inhibitor Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Influenza NA Inhibitor Market Facts & Figures by Country
3.7.1 Latin America Influenza NA Inhibitor Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Influenza NA Inhibitor Sales by Country (2019-2030)
3.7.3 Latin America Influenza NA Inhibitor Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Influenza NA Inhibitor Market Facts & Figures by Country
3.8.1 Middle East and Africa Influenza NA Inhibitor Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Influenza NA Inhibitor Sales by Country (2019-2030)
3.8.3 Middle East and Africa Influenza NA Inhibitor Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Influenza NA Inhibitor Sales by Type (2019-2030)
4.1.1 Global Influenza NA Inhibitor Sales by Type (2019-2024)
4.1.2 Global Influenza NA Inhibitor Sales by Type (2025-2030)
4.1.3 Global Influenza NA Inhibitor Sales Market Share by Type (2019-2030)
4.2 Global Influenza NA Inhibitor Revenue by Type (2019-2030)
4.2.1 Global Influenza NA Inhibitor Revenue by Type (2019-2024)
4.2.2 Global Influenza NA Inhibitor Revenue by Type (2025-2030)
4.2.3 Global Influenza NA Inhibitor Revenue Market Share by Type (2019-2030)
4.3 Global Influenza NA Inhibitor Price by Type (2019-2030)
5 Segment by Application
5.1 Global Influenza NA Inhibitor Sales by Application (2019-2030)
5.1.1 Global Influenza NA Inhibitor Sales by Application (2019-2024)
5.1.2 Global Influenza NA Inhibitor Sales by Application (2025-2030)
5.1.3 Global Influenza NA Inhibitor Sales Market Share by Application (2019-2030)
5.2 Global Influenza NA Inhibitor Revenue by Application (2019-2030)
5.2.1 Global Influenza NA Inhibitor Revenue by Application (2019-2024)
5.2.2 Global Influenza NA Inhibitor Revenue by Application (2025-2030)
5.2.3 Global Influenza NA Inhibitor Revenue Market Share by Application (2019-2030)
5.3 Global Influenza NA Inhibitor Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Green Cross
6.1.1 Green Cross Corporation Information
6.1.2 Green Cross Description and Business Overview
6.1.3 Green Cross Influenza NA Inhibitor Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Green Cross Influenza NA Inhibitor Product Portfolio
6.1.5 Green Cross Recent Developments/Updates
6.2 Roche
6.2.1 Roche Corporation Information
6.2.2 Roche Description and Business Overview
6.2.3 Roche Influenza NA Inhibitor Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Roche Influenza NA Inhibitor Product Portfolio
6.2.5 Roche Recent Developments/Updates
6.3 GlaxoSmithKline
6.3.1 GlaxoSmithKline Corporation Information
6.3.2 GlaxoSmithKline Description and Business Overview
6.3.3 GlaxoSmithKline Influenza NA Inhibitor Sales, Revenue and Gross Margin (2019-2024)
6.3.4 GlaxoSmithKline Influenza NA Inhibitor Product Portfolio
6.3.5 GlaxoSmithKline Recent Developments/Updates
6.4 Henan DaKen Chemical
6.4.1 Henan DaKen Chemical Corporation Information
6.4.2 Henan DaKen Chemical Description and Business Overview
6.4.3 Henan DaKen Chemical Influenza NA Inhibitor Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Henan DaKen Chemical Influenza NA Inhibitor Product Portfolio
6.4.5 Henan DaKen Chemical Recent Developments/Updates
6.5 ATK Chemical
6.5.1 ATK Chemical Corporation Information
6.5.2 ATK Chemical Description and Business Overview
6.5.3 ATK Chemical Influenza NA Inhibitor Sales, Revenue and Gross Margin (2019-2024)
6.5.4 ATK Chemical Influenza NA Inhibitor Product Portfolio
6.5.5 ATK Chemical Recent Developments/Updates
6.6 Chemwill Asia Co.,Ltd.
6.6.1 Chemwill Asia Co.,Ltd. Corporation Information
6.6.2 Chemwill Asia Co.,Ltd. Description and Business Overview
6.6.3 Chemwill Asia Co.,Ltd. Influenza NA Inhibitor Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Chemwill Asia Co.,Ltd. Influenza NA Inhibitor Product Portfolio
6.6.5 Chemwill Asia Co.,Ltd. Recent Developments/Updates
6.7 Shionogi Co.
6.6.1 Shionogi Co. Corporation Information
6.6.2 Shionogi Co. Description and Business Overview
6.6.3 Shionogi Co. Influenza NA Inhibitor Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Shionogi Co. Influenza NA Inhibitor Product Portfolio
6.7.5 Shionogi Co. Recent Developments/Updates
6.8 NeoPharm
6.8.1 NeoPharm Corporation Information
6.8.2 NeoPharm Description and Business Overview
6.8.3 NeoPharm Influenza NA Inhibitor Sales, Revenue and Gross Margin (2019-2024)
6.8.4 NeoPharm Influenza NA Inhibitor Product Portfolio
6.8.5 NeoPharm Recent Developments/Updates
6.9 Moksha8 Pharma
6.9.1 Moksha8 Pharma Corporation Information
6.9.2 Moksha8 Pharma Description and Business Overview
6.9.3 Moksha8 Pharma Influenza NA Inhibitor Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Moksha8 Pharma Influenza NA Inhibitor Product Portfolio
6.9.5 Moksha8 Pharma Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Influenza NA Inhibitor Industry Chain Analysis
7.2 Influenza NA Inhibitor Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Influenza NA Inhibitor Production Mode & Process
7.4 Influenza NA Inhibitor Sales and Marketing
7.4.1 Influenza NA Inhibitor Sales Channels
7.4.2 Influenza NA Inhibitor Distributors
7.5 Influenza NA Inhibitor Customers
8 Influenza NA Inhibitor Market Dynamics
8.1 Influenza NA Inhibitor Industry Trends
8.2 Influenza NA Inhibitor Market Drivers
8.3 Influenza NA Inhibitor Market Challenges
8.4 Influenza NA Inhibitor Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of TablesList of Tables
Table 1. Global Influenza NA Inhibitor Market Value Comparison by Type (2024-2030) & (US$ Million)
Table 2. Global Influenza NA Inhibitor Market Value Comparison by Application (2024-2030) & (US$ Million)
Table 3. Global Influenza NA Inhibitor Market Competitive Situation by Manufacturers in 2023
Table 4. Global Influenza NA Inhibitor Sales (Tons) of Key Manufacturers (2019-2024)
Table 5. Global Influenza NA Inhibitor Sales Market Share by Manufacturers (2019-2024)
Table 6. Global Influenza NA Inhibitor Revenue (US$ Million) by Manufacturers (2019-2024)
Table 7. Global Influenza NA Inhibitor Revenue Share by Manufacturers (2019-2024)
Table 8. Global Market Influenza NA Inhibitor Average Price (US$/Kg) of Key Manufacturers (2019-2024)
Table 9. Global Key Players of Influenza NA Inhibitor, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Influenza NA Inhibitor, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Influenza NA Inhibitor, Product Type & Application
Table 12. Global Key Manufacturers of Influenza NA Inhibitor, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Influenza NA Inhibitor by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Influenza NA Inhibitor as of 2023)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Influenza NA Inhibitor Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 17. Global Influenza NA Inhibitor Sales by Region (2019-2024) & (Tons)
Table 18. Global Influenza NA Inhibitor Sales Market Share by Region (2019-2024)
Table 19. Global Influenza NA Inhibitor Sales by Region (2025-2030) & (Tons)
Table 20. Global Influenza NA Inhibitor Sales Market Share by Region (2025-2030)
Table 21. Global Influenza NA Inhibitor Revenue by Region (2019-2024) & (US$ Million)
Table 22. Global Influenza NA Inhibitor Revenue Market Share by Region (2019-2024)
Table 23. Global Influenza NA Inhibitor Revenue by Region (2025-2030) & (US$ Million)
Table 24. Global Influenza NA Inhibitor Revenue Market Share by Region (2025-2030)
Table 25. North America Influenza NA Inhibitor Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 26. North America Influenza NA Inhibitor Sales by Country (2019-2024) & (Tons)
Table 27. North America Influenza NA Inhibitor Sales by Country (2025-2030) & (Tons)
Table 28. North America Influenza NA Inhibitor Revenue by Country (2019-2024) & (US$ Million)
Table 29. North America Influenza NA Inhibitor Revenue by Country (2025-2030) & (US$ Million)
Table 30. Europe Influenza NA Inhibitor Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 31. Europe Influenza NA Inhibitor Sales by Country (2019-2024) & (Tons)
Table 32. Europe Influenza NA Inhibitor Sales by Country (2025-2030) & (Tons)
Table 33. Europe Influenza NA Inhibitor Revenue by Country (2019-2024) & (US$ Million)
Table 34. Europe Influenza NA Inhibitor Revenue by Country (2025-2030) & (US$ Million)
Table 35. Asia Pacific Influenza NA Inhibitor Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 36. Asia Pacific Influenza NA Inhibitor Sales by Region (2019-2024) & (Tons)
Table 37. Asia Pacific Influenza NA Inhibitor Sales by Region (2025-2030) & (Tons)
Table 38. Asia Pacific Influenza NA Inhibitor Revenue by Region (2019-2024) & (US$ Million)
Table 39. Asia Pacific Influenza NA Inhibitor Revenue by Region (2025-2030) & (US$ Million)
Table 40. Latin America Influenza NA Inhibitor Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Latin America Influenza NA Inhibitor Sales by Country (2019-2024) & (Tons)
Table 42. Latin America Influenza NA Inhibitor Sales by Country (2025-2030) & (Tons)
Table 43. Latin America Influenza NA Inhibitor Revenue by Country (2019-2024) & (US$ Million)
Table 44. Latin America Influenza NA Inhibitor Revenue by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa Influenza NA Inhibitor Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 46. Middle East & Africa Influenza NA Inhibitor Sales by Country (2019-2024) & (Tons)
Table 47. Middle East & Africa Influenza NA Inhibitor Sales by Country (2025-2030) & (Tons)
Table 48. Middle East & Africa Influenza NA Inhibitor Revenue by Country (2019-2024) & (US$ Million)
Table 49. Middle East & Africa Influenza NA Inhibitor Revenue by Country (2025-2030) & (US$ Million)
Table 50. Global Influenza NA Inhibitor Sales (Tons) by Type (2019-2024)
Table 51. Global Influenza NA Inhibitor Sales (Tons) by Type (2025-2030)
Table 52. Global Influenza NA Inhibitor Sales Market Share by Type (2019-2024)
Table 53. Global Influenza NA Inhibitor Sales Market Share by Type (2025-2030)
Table 54. Global Influenza NA Inhibitor Revenue (US$ Million) by Type (2019-2024)
Table 55. Global Influenza NA Inhibitor Revenue (US$ Million) by Type (2025-2030)
Table 56. Global Influenza NA Inhibitor Revenue Market Share by Type (2019-2024)
Table 57. Global Influenza NA Inhibitor Revenue Market Share by Type (2025-2030)
Table 58. Global Influenza NA Inhibitor Price (US$/Kg) by Type (2019-2024)
Table 59. Global Influenza NA Inhibitor Price (US$/Kg) by Type (2025-2030)
Table 60. Global Influenza NA Inhibitor Sales (Tons) by Application (2019-2024)
Table 61. Global Influenza NA Inhibitor Sales (Tons) by Application (2025-2030)
Table 62. Global Influenza NA Inhibitor Sales Market Share by Application (2019-2024)
Table 63. Global Influenza NA Inhibitor Sales Market Share by Application (2025-2030)
Table 64. Global Influenza NA Inhibitor Revenue (US$ Million) by Application (2019-2024)
Table 65. Global Influenza NA Inhibitor Revenue (US$ Million) by Application (2025-2030)
Table 66. Global Influenza NA Inhibitor Revenue Market Share by Application (2019-2024)
Table 67. Global Influenza NA Inhibitor Revenue Market Share by Application (2025-2030)
Table 68. Global Influenza NA Inhibitor Price (US$/Kg) by Application (2019-2024)
Table 69. Global Influenza NA Inhibitor Price (US$/Kg) by Application (2025-2030)
Table 70. Green Cross Corporation Information
Table 71. Green Cross Description and Business Overview
Table 72. Green Cross Influenza NA Inhibitor Sales (Tons), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2019-2024)
Table 73. Green Cross Influenza NA Inhibitor Product
Table 74. Green Cross Recent Developments/Updates
Table 75. Roche Corporation Information
Table 76. Roche Description and Business Overview
Table 77. Roche Influenza NA Inhibitor Sales (Tons), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2019-2024)
Table 78. Roche Influenza NA Inhibitor Product
Table 79. Roche Recent Developments/Updates
Table 80. GlaxoSmithKline Corporation Information
Table 81. GlaxoSmithKline Description and Business Overview
Table 82. GlaxoSmithKline Influenza NA Inhibitor Sales (Tons), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2019-2024)
Table 83. GlaxoSmithKline Influenza NA Inhibitor Product
Table 84. GlaxoSmithKline Recent Developments/Updates
Table 85. Henan DaKen Chemical Corporation Information
Table 86. Henan DaKen Chemical Description and Business Overview
Table 87. Henan DaKen Chemical Influenza NA Inhibitor Sales (Tons), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2019-2024)
Table 88. Henan DaKen Chemical Influenza NA Inhibitor Product
Table 89. Henan DaKen Chemical Recent Developments/Updates
Table 90. ATK Chemical Corporation Information
Table 91. ATK Chemical Description and Business Overview
Table 92. ATK Chemical Influenza NA Inhibitor Sales (Tons), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2019-2024)
Table 93. ATK Chemical Influenza NA Inhibitor Product
Table 94. ATK Chemical Recent Developments/Updates
Table 95. Chemwill Asia Co.,Ltd. Corporation Information
Table 96. Chemwill Asia Co.,Ltd. Description and Business Overview
Table 97. Chemwill Asia Co.,Ltd. Influenza NA Inhibitor Sales (Tons), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2019-2024)
Table 98. Chemwill Asia Co.,Ltd. Influenza NA Inhibitor Product
Table 99. Chemwill Asia Co.,Ltd. Recent Developments/Updates
Table 100. Shionogi Co. Corporation Information
Table 101. Shionogi Co. Description and Business Overview
Table 102. Shionogi Co. Influenza NA Inhibitor Sales (Tons), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2019-2024)
Table 103. Shionogi Co. Influenza NA Inhibitor Product
Table 104. Shionogi Co. Recent Developments/Updates
Table 105. NeoPharm Corporation Information
Table 106. NeoPharm Description and Business Overview
Table 107. NeoPharm Influenza NA Inhibitor Sales (Tons), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2019-2024)
Table 108. NeoPharm Influenza NA Inhibitor Product
Table 109. NeoPharm Recent Developments/Updates
Table 110. Moksha8 Pharma Corporation Information
Table 111. Moksha8 Pharma Description and Business Overview
Table 112. Moksha8 Pharma Influenza NA Inhibitor Sales (Tons), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2019-2024)
Table 113. Moksha8 Pharma Influenza NA Inhibitor Product
Table 114. Moksha8 Pharma Recent Developments/Updates
Table 115. Key Raw Materials Lists
Table 116. Raw Materials Key Suppliers Lists
Table 117. Influenza NA Inhibitor Distributors List
Table 118. Influenza NA Inhibitor Customers List
Table 119. Influenza NA Inhibitor Market Trends
Table 120. Influenza NA Inhibitor Market Drivers
Table 121. Influenza NA Inhibitor Market Challenges
Table 122. Influenza NA Inhibitor Market Restraints
Table 123. Research Programs/Design for This Report
Table 124. Key Data Information from Secondary Sources
Table 125. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Influenza NA Inhibitor
Figure 2. Global Influenza NA Inhibitor Market Value Comparison by Type (2024-2030) & (US$ Million)
Figure 3. Global Influenza NA Inhibitor Market Share by Type in 2023 & 2030
Figure 4. Zanamivir Product Picture
Figure 5. Oseltamivir Product Picture
Figure 6. Peramivir Product Picture
Figure 7. Global Influenza NA Inhibitor Market Value Comparison by Application (2024-2030) & (US$ Million)
Figure 8. Global Influenza NA Inhibitor Market Share by Application in 2023 & 2030
Figure 9. Influenza A Treatment
Figure 10. Influenza B Treatment
Figure 11. Global Influenza NA Inhibitor Revenue, (US$ Million), 2019 VS 2023 VS 2030
Figure 12. Global Influenza NA Inhibitor Market Size (2019-2030) & (US$ Million)
Figure 13. Global Influenza NA Inhibitor Sales (2019-2030) & (Tons)
Figure 14. Global Influenza NA Inhibitor Average Price (US$/Kg) & (2019-2030)
Figure 15. Influenza NA Inhibitor Report Years Considered
Figure 16. Influenza NA Inhibitor Sales Share by Manufacturers in 2023
Figure 17. Global Influenza NA Inhibitor Revenue Share by Manufacturers in 2023
Figure 18. The Global 5 and 10 Largest Influenza NA Inhibitor Players: Market Share by Revenue in 2023
Figure 19. Influenza NA Inhibitor Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023
Figure 20. Global Influenza NA Inhibitor Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Figure 21. North America Influenza NA Inhibitor Sales Market Share by Country (2019-2030)
Figure 22. North America Influenza NA Inhibitor Revenue Market Share by Country (2019-2030)
Figure 23. U.S. Influenza NA Inhibitor Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 24. Canada Influenza NA Inhibitor Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 25. Europe Influenza NA Inhibitor Sales Market Share by Country (2019-2030)
Figure 26. Europe Influenza NA Inhibitor Revenue Market Share by Country (2019-2030)
Figure 27. Germany Influenza NA Inhibitor Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 28. France Influenza NA Inhibitor Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 29. U.K. Influenza NA Inhibitor Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 30. Italy Influenza NA Inhibitor Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 31. Russia Influenza NA Inhibitor Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 32. Asia Pacific Influenza NA Inhibitor Sales Market Share by Region (2019-2030)
Figure 33. Asia Pacific Influenza NA Inhibitor Revenue Market Share by Region (2019-2030)
Figure 34. China Influenza NA Inhibitor Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 35. Japan Influenza NA Inhibitor Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 36. South Korea Influenza NA Inhibitor Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 37. India Influenza NA Inhibitor Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 38. Australia Influenza NA Inhibitor Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 39. Taiwan Influenza NA Inhibitor Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 40. Indonesia Influenza NA Inhibitor Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 41. Thailand Influenza NA Inhibitor Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 42. Malaysia Influenza NA Inhibitor Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 43. Philippines Influenza NA Inhibitor Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 44. Latin America Influenza NA Inhibitor Sales Market Share by Country (2019-2030)
Figure 45. Latin America Influenza NA Inhibitor Revenue Market Share by Country (2019-2030)
Figure 46. Mexico Influenza NA Inhibitor Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 47. Brazil Influenza NA Inhibitor Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 48. Argentina Influenza NA Inhibitor Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 49. Middle East & Africa Influenza NA Inhibitor Sales Market Share by Country (2019-2030)
Figure 50. Middle East & Africa Influenza NA Inhibitor Revenue Market Share by Country (2019-2030)
Figure 51. Turkey Influenza NA Inhibitor Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 52. Saudi Arabia Influenza NA Inhibitor Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 53. UAE Influenza NA Inhibitor Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 54. Global Sales Market Share of Influenza NA Inhibitor by Type (2019-2030)
Figure 55. Global Revenue Market Share of Influenza NA Inhibitor by Type (2019-2030)
Figure 56. Global Influenza NA Inhibitor Price (US$/Kg) by Type (2019-2030)
Figure 57. Global Sales Market Share of Influenza NA Inhibitor by Application (2019-2030)
Figure 58. Global Revenue Market Share of Influenza NA Inhibitor by Application (2019-2030)
Figure 59. Global Influenza NA Inhibitor Price (US$/Kg) by Application (2019-2030)
Figure 60. Influenza NA Inhibitor Value Chain
Figure 61. Influenza NA Inhibitor Production Process
Figure 62. Channels of Distribution (Direct Vs Distribution)
Figure 63. Distributors Profiles
Figure 64. Bottom-up and Top-down Approaches for This Report
Figure 65. Data Triangulation
Figure 66. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
